Anticipated Milestones: Clinical Trial Readouts: Top-line data from pivotal TRANQUILITY II trial in Q2 2023; Top-line efficacy data from pivotal SERENITY III trial in Q2 2023; Top-line results from Phase 1b MAD trial for MDD program in Q2 2023. Clinical Trial Initiations; Initiate SERENITY III Part 2 in Q2 2023;Initiate Phase 2b potential pivotal study of BXCL701 in SCNC in 2H 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
- BioXcel Therapeutics to participate in a conference call with Truist
- BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
- BioXcel Therapeutics to hold Key Opinion Leader Day
- BioXcel Therapeutics price target raised to $79 from $73 at H.C. Wainwright
